3-(1H-苯并咪唑-2-基)-2-甲基-苯胺 | 428856-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 3-(1H-苯并咪唑-2-基)-2-甲基-苯胺
• 英文名称: 3-(1H-benzimidazol-2-yl)-2-methylaniline
• 英文别名: 3-(1H-Benzoimidazol-2-yl)-2-methyl-phenylamine
• CAS: 428856-24-0
• 化学式: C₁₄H₁₃N₃
• mdl: MFCD02628441
• 分子量: 223.277
• InChiKey: IJUMYEWHEBWLDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-氯烟酸 、 3-(1H-苯并咪唑-2-基)-2-甲基-苯胺 、 cis-2,6-dimethylmorpholine 、 N-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-6-((2S,6R)-2,6-dimethylmorpholino)nicotinamide 、 生成 N-(3-(1H-benzo[d]imidazol-2-yl)-2-methylphenyl)-6-((2S,6R)-2,6-dimethylmorpholino)nicotinamide
  参考文献：
  名称：

  N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof

  摘要：

  本发明涉及一种新型的N-(3-杂环芳基芳基)-4-芳基芳基羧酰胺及其类似物，其化学式为I式，其中C为环状基团，D1-D4、Q1、Q2、R5在此定义。具有I式的化合物是刺猬通路抑制剂。因此，本发明的化合物可用于治疗对刺猬活性抑制有反应的临床疾病，如癌症。

  公开号：

  US20150191460A1
• 作为产物：
  描述：

  2-甲基-3-硝基苯甲酸 在 吡啶 、 4-二甲氨基吡啶 、 草酰氯 、 10% palladium on activated carbon 、 氢气 、 对甲苯磺酸 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 对二甲苯 、 乙酸乙酯 为溶剂， 反应 22.75h， 生成 3-(1H-苯并咪唑-2-基)-2-甲基-苯胺
  参考文献：
  名称：

  Design and Synthesis of 2-Arylbenzimidazoles and Evaluation of Their Inhibitory Effect against Chlamydia pneumoniae

  摘要：

  Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer's disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 mu M, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 mu M against CWL-029 and 6.3 mu M against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.

  DOI：

  10.1021/jm1008083

文献信息

• [EN] N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF<br/>[FR] N-(3-HÉTÉROARYLARYL)-4-ARYLARYLCARBOXAMIDES ET ANALOGUES COMME INHIBITEURS DE LA VOIE HEDGEHOG ET LEUR UTILISATION
  申请人：IMPACT THERAPEUTICS INC

  公开号：WO2014012511A1

  公开（公告）日：2014-01-23

  Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D1-D4, Q1, Q2, R5 are defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer.

  揭示了一种新颖的N-(3-杂环芳基芳基)-4-芳基芳基羧酰胺及其类似物，表示为公式I：其中C是环状基团，D1-D4，Q1，Q2，R5在此定义。具有公式(I)的化合物是刺猬通路抑制剂。因此，本发明的化合物可用于治疗对刺猬活性抑制敏感的临床病况，如癌症。
• N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof
  申请人：IMPACT Therapeutics, Inc.

  公开号：US10676468B2

  公开（公告）日：2020-06-09

  Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D1-D4, Q1, Q2, R5 are defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer.

  公开了新型 N-(3-异芳基)-4-芳基羧酰胺及其类似物，由式 I 表示：其中 C 环基、D1-D4、Q1、Q2、R5 在此定义。具有式（I）的化合物是刺猬通路抑制剂。因此，本发明的化合物可用于治疗对抑制刺猬活性有反应的临床病症，如癌症。
• N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF
  申请人：Impact Therapeutics, Inc.

  公开号：EP2875005B1

  公开（公告）日：2020-11-11
• Design and Synthesis of 2-Arylbenzimidazoles and Evaluation of Their Inhibitory Effect against <i>Chlamydia pneumoniae</i>
  作者：Leena Keurulainen、Olli Salin、Antti Siiskonen、Jan Marco Kern、Joni Alvesalo、Paula Kiuru、Matthias Maass、Jari Yli-Kauhaluoma、Pia Vuorela

  DOI：10.1021/jm1008083

  日期：2010.11.11

  Chlamydia pneumoniae is an intracellular bacterium that responds poorly to antibiotic treatment. Insufficient antibiotic usage leads to chronic infection, which is linked to disease processes of asthma, atherosclerosis, and Alzheimer's disease. The Chlamydia research lacks genetic tools exploited by other antimicrobial research, and thus other approaches to drug discovery must be applied. A set of 2-arylbenzimidazoles was designed based on our earlier findings, and 33 derivatives were synthesized. Derivatives were assayed against C. pneumoniae strain CWL-029 in an acute infection model using TR-FIA method at a concentration of 10 mu M, and the effects of the derivatives on the host cell viability were evaluated at the same concentration. Fourteen compounds showed at least 80% inhibition, with only minor changes in host cell viability. Nine most potential compounds were evaluated using immunofluorescence microscopy on two different strains of C. pneumoniae CWL-029 and CV-6. The N-[3-(1H-benzimidazol-2-yl)phenyl]-3-methylbenzamide (42) had minimal inhibitory concentration (MIC) of 10 mu M against CWL-029 and 6.3 mu M against the clinical strain CV-6. This study shows the high antichlamydial potential of 2-arylbenzimidazoles, which also seem to have good characteristics for lead compounds.
• N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof
  申请人：IMPACT Therapeutics, Inc.

  公开号：US20150191460A1

  公开（公告）日：2015-07-09

  Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D 1 -D 4 , Q 1 , Q 2 , R 5 are defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer.

  揭示了一种新型的N-(3-杂环芳基芳基)-4-芳基芳基羧酰胺及其类似物，其化学式如下：其中C为环状基团，D1-D4，Q1，Q2，R5在此处定义。具有化学式(I)的化合物是刺猬途径抑制剂。因此，本发明的化合物可用于治疗对刺猬活性抑制有响应的临床病况，如癌症。